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Abstract
Purpose Hyperthermic intrathoracic chemotherapy (HITOC) is an additive, intraoperative treatment for selected malignant 
pleural tumors. To improve local tumor control, the thoracic cavity is perfused with a cisplatin-containing solution after 
surgical cytoreduction. Since cisplatin is probably carcinogenic to humans, potential contamination of surfaces and path-
ways of exposure should be systematically investigated to enable risk assessments for medical staff and thus derive specific 
recommendations for occupational safety.
Methods Wipe sampling was performed at pre-selected locations during and after ten HITOC procedures, including on the 
surgeon’s gloves, for the quantitation of surface contaminations with cisplatin. After extraction of the samples with hydro-
chloric acid, platinum was determined as a marker for cisplatin by voltammetry.
Results High median concentrations of cytostatic drugs were detected on the surgeons’ (1.73 pg Cis-Pt/cm2, IQR: 9.36 pg 
Cis-Pt/cm2) and perfusionists’ (0.69 pg Cis-Pt/cm2, IQR: 1.73 pg Cis-Pt/cm2) gloves. The display of the perfusion device 
showed partially elevated levels of cisplatin up to 4.92 pg Cis-Pt/cm2 and thus could represent an origin of cross-contami-
nation. In contrast, cisplatin levels on the floor surfaces in the area of the surgeon and the perfusion device or in the endo-
bronchial tube were relatively low.
Conclusion With a correct use of personal protective equipment and careful handling, intraoperative HITOC appears to be 
safe to perform with a low risk of occupational exposure to cisplatin.
Keywords Hyperthermic intrathoracic chemotherapy · HITOC · Cisplatin · Surface contamination · Occupational exposure
Introduction
Hyperthermic intrathoracic chemotherapy (HITOC) is an 
innovative, additive treatment for selected patients with pri-
mary or secondary malignant pleural tumors. In Germany, 
about 350 of these procedures have been performed in 
10 years by 17 specialized clinics, and the number is increas-
ing (Ried et al. 2018). Over a period of 60 min, the tho-
racic cavity is perfused with a heated solution to improve 
local tumor control after surgical cytoreduction (Ried et al. 
2013). There is no international standardized procedure for 
the intra- and perioperative care of HITOC patients (Ried 
et al. 2016; Zhou et al. 2017). However, the perfusion solu-
tion always contains cisplatin in a dosage between 50 and 
250 mg/m2 body surface area (Maury et al. 2017; Zellos 
et al. 2009; Zhou et al. 2017). High local concentrations of 
cisplatin can be achieved in the lung tissue down to a median 
depth of 3–4 mm and thus induce cell death of residual 
tumor cells by the intracavitary cisplatin lavage (Ried et al. 
2015; Cregan et al. 2013). The results on long-term survival 
are promising (Markowiak et al. 2019; Ambrogi et al. 2018). 
Cisplatin is probably carcinogenic for humans and, there-
fore, represents a potential risk for the healthcare personnel 
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(Falck et al. 1979; International Agency for Research on 
Cancer; Pethran et al. 2003; Dranitsaris et al. 2005). For this 
reason, occupational exposure should always be avoided and 
a cautious handling and the use of protective equipment is 
mandatory.
Dermal uptake was identified to be the most likely route 
of occupational exposure to antineoplastic drugs in health-
care settings (Kromhout et al. 2000; Sessink et al. 1994). 
As a result, Pethran et al. demonstrated that platinum excre-
tion of pharmacy employees preparing cytostatic agents 
is significantly higher during the working shift (Pethran 
et al. 2003). Also in the hospital setting an incorporation 
by administering employees could be observed, since it 
has been demonstrated that the urine of healthcare workers 
after occupational exposure to chemotherapeutic agents was 
mutagenic to indicator organisms like Escherichia coli and 
Salmonella typhimurium (Falck et al. 1979). Furthermore, 
a meta-analysis showed a 46% increase in the risk of spon-
taneous abortion for female medical personal after exposure 
to chemotherapeutic agents (Dranitsaris et al. 2005). These 
results urge caution, but dermal contact can be prevented 
by taking the appropriate safety measures (Landeck et al. 
2015). To prevent the exposure of the operating room (OR) 
personnel, specific safety regulations must be applied (safety 
instruction, gloves compatible with cytostatic drugs, protec-
tive surgical gowns, safety glasses, dedicated containers for 
disposal of cytostatic agents) (Ried et al. 2018).
In this context, the intraoperative application of cytostatic 
drugs is a challenge for the surgeon, since this procedure 
requires high demands on the tightness of wound and drain-
age sutures. Leaking perfusion solution can represent a haz-
ard for the personnel through direct or indirect contact with 
contaminated surfaces. Another specific aspect of HITOC is 
the close physical distance of the intrathoracic volume and 
the bronchial system. It is unclear if the patient’s bronchial 
secretion contains cisplatin and, therefore, may lead to con-
tamination of materials used in ventilation of the patient.
Since cytostatic drugs are only used in a few proce-
dures in the environment of the OR, there are only few 
studies assessing a possible risk to the personnel in this 
regard. The aim of this study was the identification of vul-
nerable locations in the OR to prevent distribution of the 
substance. These findings can be used to verify adequate 
protective measures for the staff. In contrast to oncological 
wards, handling of cytostatic drugs is often unfamiliar to 
staff of an OR. This can result in distrust of the intraopera-
tive HITOC. The objectives of this study was to evaluate 
the occupational safety of HITOC in terms of exposure to 
cisplatin for the medical staff and allow specific recom-
mendations for the operative working environment.
Methods
Study design
This prospective observational study considered all 
patients who received HITOC after surgical cytoreduc-
tion between January 2020 and November 2020 in the 
University Hospital Regensburg and the Hospital of Bar-
mherzige Brüder Regensburg. Patients with less than 
60 min of intrathoracic perfusion or an intrathoracic dose 
of cisplatin other than 175 mg/m2 body surface area (BSA) 
were excluded. The primary endpoint of the study was 
the potential exposure of the surgical staff to cisplatin via 
surfaces during HITOC. For this purpose, a quantitative 
detection of platinum as a marker for the cytostatic drug 
cisplatin on defined surfaces in the OR was performed. 
The approval of the ethics committee of the University 
Regensburg was obtained (Reference number: 20-1698-
101). Informed consent was waived, as the examinations 
do not affect the patient or change the procedure of the 
HITOC and only serve quality assurance and safety at 
work.
HITOC
The HITOC was conducted after the resection of the pleu-
ral tumor manifestations, which was performed always with 
the aim of a macroscopic complete tumor resection. The 
thoracotomy was closed after insertion of one inflow and 
two to three outflow drains. After connecting the drainages 
to the perfusion system, the patient’s thorax was evacuated 
by adding a priming volume of 3–4 l isotonic (0.9%) sodium 
chloride solution to remove air until a stable perfusion cir-
cuit was obtained. Once a temperature of 42 °C was reached 
at the outflow drainage, the chemotherapeutic agents were 
injected into the circulation as a bolus. The total volume 
of solution in the circulation varied depending on the indi-
vidual dimensions of the thoracic cavity. The dosage of cis-
platin was 175 mg/m2 body surface area in all patients. After 
completion of the 60-min HITOC, the perfusion volume was 
passively released and the drainages were connected to the 
chest drainage units. The tube and reservoir system were 
disposed in dedicated containers for cytostatic drugs and 
the perfusion device was cleaned. The patient was regularly 
extubated in the OR. The duration between completion of 
the HITOC and subsequent cleaning of the entire OR usually 
is about 20 min.
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Sampling sites
In total, six surface sampling areas were defined: display 
(touch screen) of the perfusion device (228  cm2), the floor 
area below the perfusor (900  cm2), the floor area below the 
surgeon (900  cm2), the inside of the breathing tube and the 
outside surface of both gloves (palm area, approximately 
200  cm2) of the surgeon and the perfusionist directly after 
the end of the perfusion (Fig. 1). The display and the floor 
locations were sampled before the start of the surgery (clean-
ing), at the beginning of the perfusion and at the end of the 
perfusion to adjust for circumstantial contaminations by pre-
vious surgeries (Fig. 2). Blank samples from the gloves and 
the breathing tube were taken at the beginning of the study.
Wiping procedure
The wipe sampling followed an established procedure 
(Schmaus et al. 2002). In detail, each surface was consecu-
tively wiped with three circular filters papers (Quantitative 
Grade 391 Filter Papers, 90 mm diameter, Sartorius, Göttin-
gen, Germany), which were folded to an easy-to-hold shape 
with a final wiping surface of ~ 7.5  cm2. Immediately prior 
to the sampling, the filters were moistened with 0.1% hydro-
chloric acid, except for the perfusor touch display, which 
was wiped with 0.9% sodium chloride solution. For each 
sampling location, a new pair of gloves was used to avoid 
cross-contamination. The filters for each sampling location 
were collected into a single screw-cap glass container, trans-
ported to the laboratory and stored at room temperature until 
analysis.
Analytical procedure
Total platinum (Pt) concentrations in wipe samples 
were determined as a marker for cisplatin. For analy-
sis, the wipe samples were extracted with 2% hydro-
chloric acid for 1  h and analyzed by voltammetry as 
Fig. 1  Demonstration of the perfusion setup. The picture shows the 
perfusion device with connected drainages and a marked area for 
wipe sampling in front. The cytostatic agents are injected above this 
area after a stable circulation has been established
Fig. 2  Overwiew of the sampling procedure
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described previously (Ensslin et al. 1994). In detail, 1 ml 
of the extract was transferred into a quartz vessel and 
5 ml ultrapure water, 100 µl sulfuric acid (96%, Merck 
suprapur) and 200 µl hydrogen peroxide (30%, Merck 
suprapur) were added. The samples were UV-irradi-
ated for 2 h using a MAUV-2X UV digestor (Maassen, 
Reutlingen, Germany) and afterwards analyzed by vol-
tammetry for Pt determination (Methrom, Filderstadt, 
Germany). The quantitation was based on the standard 
addition method. In detail, between 10 and 100 pg of 
platinum (as  H2PtCl6, 2.1 µg/l in 1% sulfuric acid) were 
added directly to the sample after initial the voltammet-
ric analysis. Finally, platinum levels of the samples were 
multiplied by 1.54 to obtain cisplatin levels.
Statistical analysis
First, the data were collected in tabular form using Excel, 
Version 15.0 (Microsoft Corporation, Redmond, USA). 
Blank values were subtracted from the results. After-
wards, statistical analysis was performed using IBM SPSS 
Statistics, Version 26 (IBM Corporation, Armonk, USA). 
All data are presented as median and interquartile range 
(IQR). Mean platinum levels were tested against guid-
ance values reported in the literature using a one-sample 
t test (Schierl et al. 2009). In detail, a low contamination 
was defined at cisplatin levels < 0.9 pg/cm2, a moderate 
contamination at cisplatin levels between 0.9 and 6 pg/
cm2 and a severe contamination at cisplatin levels > 6 pg/
cm2 (Schierl et al. 2009). The differences were considered 
significant for a p value of less than 0.05.
Results
The results for each sampling location are given in Table 1. 
Corresponding box plots of the post-HITOC results are shown 
in Fig. 3. In the following, the individual locations of possible 
direct or indirect contamination in the OR are described. 
Gloves
The highest median levels of Cis-Pt (cisplatin) were found 
on the surgeon’s gloves (1.73 pg Cis-Pt/cm2) followed by the 
gloves of the perfusionist (0.69 pg Cis-Pt/cm2). However, 
the results showed a high variance. In five samples (50%) 
cisplatin levels on the surgeon’s gloves showed a moder-
ate contamination and four (40%) were severely contami-
nated (> 6 pg Cis-Pt/cm2). The gloves of the perfusionist 
showed significantly lower contamination. In fact, only three 
samples (30%) were moderately contaminated. In the one-
sample t test the surface contamination of the perfusionist’s 
glove lies significantly below the reference value of a severe 
contamination (p < 0.001; Table 2). 
Perfusion device
Relatively high concentrations were also observed on the 
touch display of the perfusion device. It is worth mentioning 
Table 1  Summary of the wipe sampling results
GM geometric mean, Cis-Pt cisplatin, N.a not applicable, SD standard deviation
a For single-use products, the pre-procedural value was measured once
Sampling location Sample area 
 (cm2)
GM Minimum 25th percentile Median 75th percentile Maximum
pg Cis-Pt/cm2
Gloves  surgeona 200 2.50 0.23 1.02 1.73 10.38 49.06
Floor surgeon (pre) 900 0.11 0.02 0.07 0.12 0.23 0.60
Floor surgeon (post) 900 0.16 0.02 0.13 0.16 0.26 1.14
Gloves  perfusionista 200 0.86 0.15 0.37 0.69 2.10 8.54
Display perfusor (pre) 228 0.50 0.04 0.24 0.57 1.28 3.37
Display perfusor (post) 228 0.59 0.13 0.20 0.44 1.64 4.92
Floor perfusor (pre) 900 0.16 0.07 0.08 0.21 0.25 0.31
Floor perfusor (post) 900 0.23 0.04 0.08 0.15 0.37 13.62
Sampling location Sample area 
 (cm2)
GM Minimum 25th percentile Median 75th percentile Maximum
ng Cis-Pt
Breathing tube (post)a N.a 0.13 0.03 0.06 0.15 0.33 0.40
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that two moderate (20%) and one severe (10%) contamina-
tions were observed at this location in the cleaning sample 
already. After HITOC, there were only three (30%) samples 
found in moderate contamination ranges. Comparing the val-
ues of the display before and after HITOC, no clear trend 
is apparent since the individual value of the sample before 
perfusion was sometimes even higher than after HITOC 
(Fig. 4). The mean cisplatin level of 1.16 pg Cis-Pt/cm2 on 
the display was significantly below the reference value of a 
severe contamination (p < 0.001) (Table 2).
Floor
In the floor area next to the perfusion device as well as on 
the opposite side, platinum could be detected both before 
and after the HITOC. At both locations, however, observed 
values were low after HITOC and below the lower refer-
ence range of 0.9 pg Cis-Pt/cm2 in 90% of cases. In one 
case (10%) the cisplatin level next to the perfusion device 
increased from 0.24 pg/cm2 pre-HITOC to 13.62 pg/cm2 
post-HITOC which represented a severe contamination. One 
sample (10%) of the opposite floor surface was classified as 
Fig. 3  Cisplatin contamina-
tion on surfaces in the OR after 
HITOC. Yellow Line: 0.9 pg 
Cis-Pt/cm2 (moderate contami-
nation). Red line: 6 pg Cis-Pt/
cm2 (severe contamination). ∘: 
mild outlier (distance to quar-
tiles between 1.5 and 3 times 
the interquartile range (IQR), * : 
extreme outlier (distance to 
quartiles greater than 3 times 
the IQR (color figure online)
Table 2  One sample t test of contamination after HITOC to reference values
Cis-Pt cisplatin, CI confidence interval, SD standard deviation
*Statistical significance
Mean ± SD Test value = 0.9 pg Pt/cm2 Test value = 6 pg Pt/cm2
Mean difference 95% CI of the differ-
ence
p value Mean difference 95% CI of the dif-
ference
p value
Gloves surgeon (pg 
Cis-Pt/cm2)
(n = 10)
9.51 ± 15.3 8.61  − 2.3–19.6 0.109 3.51  − 7.4 to 14.5 0.486
Gloves perfusionist (pg 
Cis-Pt/cm2)
(n = 10)




1.16 ± 1.56 0.26  − 0.9–1.4 0.614  − 4.84  − 6 to − 3.7  < 0.001*
Floor perfusion system 
(pg Cis-Pt/cm2)
(n = 10)
1.53 ± 4.26 0.63  − 2.4–3.7 0.651  − 4.47  − 7.5 to 1.4 0.009*
Floor surgeon (pg Cis-
Pt/cm2)
(n = 10)
0.26 ± 0.32  − 0.64  − 0.9 to − 0.4  < 0.001*  − 5.74  − 6 to − 5.5 < 0.001*
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moderate contamination. The data revealed no clear trend 
between cleaning, pre-surgery and post-surgery samples 
(Fig. 4). Both floor areas had levels significantly below the 
reference value of a severe contamination in the one-sample 
t test (p = 0.009 and < 0.001).
Endobronchial tube
After extubation, the endobronchial tube was wiped endo-
luminally. The tube thus contained condensed breathing air 
from the patient. Compared to the other investigated loca-
tions, the wiped area in the endobronchial tube was very 
small (~ 7.5  cm2). Therefore, the differences in the observed 
cisplatin concentration before and after HITOC consisted 
of minimal changes in the absolute values. A conversion to 
a surface concentration would disproportionately represent 
these minimal deviations, so that the absolute values are 
shown. Absolute levels of cisplatin (median: 0.15 ng Cis-Pt) 
in the endobronchial tube were relatively low, but higher 
than the blank sample (0.05 ng Cis-Pt).
Discussion
It has been previously demonstrated that intraoperative 
chemotherapy methods, e.g. Hyperthermic Intraperitoneal 
Chemotherapy (HIPEC) and Pressurized Intraperitoneal 
Aerosol Chemotherapy (PIPAC), can result in substantial 
contamination of OR surfaces with the applied cytostatic 
drugs. For both surgical methods, surface contaminations 
were observed on the perfusion device, the floor and the 
gloves of surgeons and perfusionists. However, the studies 
showed that surgeries with overall low contaminations and 
occupational exposure are possible if adequate occupational 
safety and cleaning standards are ensured during and after 
these surgical procedures (Ametsbichler et al. 2018; Schierl 
et al. 2012). However, the contamination of surfaces in the 
OR’s working environment during HITOC remains unclear.
In our study, cisplatin levels on individual OR surfaces 
showed median values of 0.12–1.73 pg Cis-Pt/cm2. There 
were some considerable outliers with values of up to 49 pg 
Cis-Pt/cm2 on the gloves of the surgeon. Also in the context 
of intraabdominal procedures such as HIPEC and PIPAC 
samples widely ranged and outliers were detected with 
platinum concentrations up to 110.000 pg Pt/cm2 (equals 
169.000 pg/cm2 Cis-Pt) on the reservoir of the perfusion 
device (Schierl et al. 2012; Ametsbichler et al. 2018).
There are no threshold values for surface contaminations 
with cytostatic drugs. However, contaminations with carci-
nogenic as well as probably carcinogenic substances should 
be as low as possible to avoid circumstantial exposure. Most 
experience in this regard exists in the setting of pharma-
cies preparing cytostatic drugs, where contamination was 
detected on surfaces throughout the entire room with maxi-
mum values of 100 pg Pt/cm2 (Brouwers et al. 2007; Mason 
et  al. 2005). After examining 102 German pharmacies, 
Schierl et al. introduced the 50th (0.6 pg Pt/cm2 ≙ 0.9 pg 
cisplatin/cm2) and 75th (4 pg Pt/cm2 ≙ 6 pg cisplatin/cm2) 
percentiles of the platinum analysis in 1008 wipe samples 
as guidance values to compare the results between different 
locations (Schierl et al. 2009).
In our study, the wipe samples of the surgeon’s gloves 
showed the highest level of contamination. This localization 
was also the only one with a median contamination level above 
the reference value of 0.9 pg Cis-Pt/cm2 (moderate contami-
nation), all other localizations were below it. Since they are 
disposed of immediately after HITOC, the risk of exposure 
and cross-contamination in clinical practice can be presumed 
to be low if the gloves are disposed properly. Besides a perfu-
sion on the closed chest performed in this study, perfusion with 
an open chest is also performed in some clinics internationally 
(Ried and Hofmann 2013). This approach is certainly likely to 
result in significantly higher levels of glove contamination. On 
average, the contaminations on the other surfaces were rela-
tively low and showed no clear trend between cleaning, pre-
surgery and post-surgery samples (Fig. 4). In some cases, the 
cleaning samples showed even higher levels of contamination 
than those before and after HITOC. On the one hand, this can 
be explained by the fact that the perfusion device was occa-
sionally also used for other procedures such as HIPEC. On the 
Fig. 4  Individual cisplatin levels on the perfusor display (a), the floor below the perfusor (b) and the floor below the surgeon (c) before and after 
HITOC
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other hand, this contamination may be caused by accidental 
cross-contamination due to the final cleaning of the perfusion 
device. However, after one HITOC, cisplatin levels on the dis-
play (4.92 vs 2.29 pg/cm2) and the floor next to the perfusion 
device (13.62 vs 0.24 pg/cm2) were clearly higher compared 
than in samples taken at the start of the procedure. This may 
be explained by an accidental spillage of the cisplatin solution 
during the procedure and subsequent cross-contamination. In 
fact, cisplatin levels of the perfusionist’s glove (2.00 pg/cm2) 
from the same day were relatively high, too. These pre-surgery 
and post-surgery samples in our samples should be addressed 
by a thorough cleaning procedure of the perfusion device after 
HITOC. We recommend cleaning of critical surfaces using a 
two-step procedure by first using an aqueous cleaning agent 
followed by an alcoholic solution (e.g. 70% isopropanol) 
directly after finishing HITOC.
The floor areas showed similar values in median after 
HITOC both close to the perfusion device and further away, 
but the variability of contamination close to the perfusion 
device was considerably higher. This can be explained by the 
fact that the cytostatics were introduced into the circulation 
directly above this test area, thus posing a risk of uninten-
tional spillage of the substances. In one HITOC, cisplatin 
levels on the floor next to the surgeon increased from 0.10 at 
the start to 1.14 pg/cm2 after the procedure. Again, this may 
be caused by an accidental spillage during the perfusion or 
undetected leakage of surgical wounds.
We also investigated the potential contamination of the 
breathing tube as a potential source of airborne exposure 
to cisplatin. Therefore, we wiped the endobronchial tube 
endoluminally and thus collected condensed exhaled breath 
of the patient. The endobronchial tube showed cisplatin lev-
els above the blank value, although in very small amounts. 
Since the measurement was taken in a distance from the 
distal end of the tube (> 10 cm) it can, therefore, be assumed 
that patients’ breathing air contained cisplatin during/after 
HITOC. Due to its high molecular weight, cisplatin’s vapor 
pressure is low, and so is its tendency to form aerosols (Con-
nor et al. 2000). However, there is a possibility that cisplatin 
may be transported with aerosol from the respiratory tract 
and thus may be eventually released. The possibility of air-
borne exposure to cisplatin in healthcare settings has rarely 
been addressed in the literature (deWerk Neal et al. 1983; 
Ametsbichler et al. 2018). During one HITOC, we sampled 
ambient air of the patient after extubation for platinum anal-
ysis, but levels were below the limit of detection (data not 
shown). Similar results have been reported by Ametsbichler 
et al. for PIPAC (Ametsbichler et al. 2018). Thus, further air 
sampling was waived. Based on these measurements and the 
results of the samples on the endobronchial tube we believe 
that the risk of airborne particle inhalation during and after 
HITOC is very low and that the risk of dermal exposure 
is more relevant for employees. Consequently, personal 
protective equipment consisting of protective gloves and 
gowns should be used in airway management and other 
situations where there is a risk of direct contact with body 
secretions.
Conclusion
Hyperthermic intrathoracic chemotherapy is generally safe 
to perform, but there are critical areas to consider. After 
each use, the perfusion device should be thoroughly cleaned 
in a two-step procedure by first using an aqueous cleaning 
agent followed by an alcoholic solution. The risks of direct 
contact with the cytostatic drug can be minimized very well 
by a correct use of personal protective equipment and careful 
handling. During and after HITOC, the protective equip-
ment should include gloves, reinforced gowns, and safety 
glasses to prevent dermal uptake. Gloves should be worn for 
any patient contact or contact with near-patient surfaces and 
disposed of immediately afterwards.
Limitations
In this study, only selected sites were monitored that the 
authors felt to be especially relevant for direct contact to cis-
platin or as an origin of cross-contamination. No systematic 
ambient air study has been conducted to evaluate airborne 
transmission of cisplatin. The examination of the endobron-
chial tube in this regard represents only indirect evidence of 
aerosol-bound transmission. Although our results suggest 
that the risk of an accidental exposure of the OR personnel 
to cisplatin can be considered to be very low, biomonitoring 
would have been necessary to ultimately exclude any uptake 
of cisplatin.
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